Urolog. pro Praxi, 2011; 12(1): 7-11

Combined treatment for lower urinary tract symptoms and benign prostatic hyperplasia

MUDr. Michaela Matoušková, doc. MUDr. Miroslav Hanuš, CSc.
Urocentrum, Praha

Pharmacotherapy for lower urinary tract symptoms (LUTS) has become the preferred therapeutic modality over the years. Monotherapy

fails to have a sufficient effect on LUTS in a proportion of patients and, thus, to have an effect on their quality of life. In these patients,

combined treatment can be the solution. Rational prescribing allows to individualize the pharmacological approach to the treatment

for lower urinary tract symptoms.

Keywords: LUTS, BPH, pharmacotherapy, combined treatment

Published: February 25, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matoušková M, Hanuš M. Combined treatment for lower urinary tract symptoms and benign prostatic hyperplasia. Urol. praxi. 2011;12(1):7-11.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175(5): 999-1004 (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/16469601. Go to original source... Go to PubMed...
    2. Kaplan SA, Roehrborn CG, Chancellor M, et al. Extendedrelease tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008; 102(9): 1133-1139 (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/18510659. Go to original source... Go to PubMed...
    3. Roehrborn CG, Kaplan SA, Kraus SR, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008; 72(5): 1061-1067 (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/18817961. Go to original source... Go to PubMed...
    4. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC, McCarthy C, Geffriaud-Ricouard C, on behalf of the European ALFIN Study Group. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 34(3): 169-175. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/9732187. Go to original source... Go to PubMed...
    5. Kirby R, Roehrborn CG, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB, Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61(1): 119-126. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/12559281. Go to original source... Go to PubMed...
    6. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335(8): 533-539. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/8684407. Go to original source... Go to PubMed...
    7. McConnell JD, Roehrborn CG, Bautista O, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349(25): 2387-2398. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/14681504. Go to original source... Go to PubMed...
    8. Roehrborn CG, Siami P, Barkin J, Dami?o R, Major-Walker K, Morrill B, Montorsi F, CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the ComAT study. J Urol 2008; 179(2): 616-621. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/18082216. Go to original source... Go to PubMed...
    9. Roehrborn CG, Siami P, Barkin J, Dami?o R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57(1): 123-131. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/19825505. Go to original source... Go to PubMed...
    10. Barkin J, Guimar?es M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alphareductase inhibitor dutasteride. Eur Urol 2003; 44(4): 461-466. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/14499682. Go to original source... Go to PubMed...
    11. Nickel JC, Barkin J, Koch C, et al. Finasteride monotherapy maintains stable košer urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J 2008; 2(1): 16-21. (Level 2b). http://www.ncbi.nlm.nih.gov/pubmed/18542722. Go to original source... Go to PubMed...
    12. Hvistendahl GM, Riis A, Norgaard JP, Djurhuus JC. The pharmacokinetics of 400 ?g of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect. BJU Int 2005; 95(6): 804-809. (Level 2b). http://www.ncbi.nlm.nih.gov/pubmed/15794787. Go to original source... Go to PubMed...
    13. Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol 2004; 60(6): 397-402. (Level 2b). http://www.ncbi.nlm.nih.gov/pubmed/15197520. Go to original source... Go to PubMed...
    14. Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006; 25(2): 105-109. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/16304673. Go to original source... Go to PubMed...
    15. Asplund R, Sundberg B, Bengtsson P. Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU Int 1999; 83: 591-595. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/10233563. Go to original source... Go to PubMed...
    16. van Kerrebroeck P, Rezapour M, Cortesse A, Thüroff J, Rijs A, Norgaard JP. Desmopressin in the treatment of nocturia: a double blind placebo-controlled study. Eur Urol 2007; 52(1): 221-229. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/17280773. Go to original source... Go to PubMed...
    17. Ückert S, Küthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nukleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166(6): 2484-2490. (Level 2b). http://www.ncbi.nlm.nih.gov/pubmed/11696815. Go to original source... Go to PubMed...
    18. Ückert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006; 49(4): 740-745. (Level 2b). http://www.ncbi.nlm.nih.gov/pubmed/16460876. Go to original source... Go to PubMed...
    19. Andersson KE, Persson K. Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Scand J Urol Nephrol Suppl 1995; 175: 43-53. (Level 4). http://www.ncbi.nlm.nih.gov/pubmed/8771275.
    20. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on košer urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662-667. (Level 3). http://www.ncbi.nlm.nih.gov/pubmed/16839322. Go to original source... Go to PubMed...
    21. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90(9): 836-839. (Level 3). http://www.ncbi.nlm.nih.gov/pubmed/12460342. Go to original source... Go to PubMed...
    22. Guven EO, Balbay MD, Mete K, Serefoglu EC. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and sympotomatic benign prostatic hyperplasia. Int Urol Nephrol 2009; 41(2): 287-292. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/18649004. Go to original source... Go to PubMed...
    23. Roehrborn CG, Kaminetsky JC, Auerbach SM, et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010; 105(4): 502-507. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/19732051. Go to original source... Go to PubMed...
    24. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5(9): 2170-2178. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/18638006. Go to original source... Go to PubMed...
    25. Liquori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009; 6(2): 544-552. (Level 1b). http://www.ncbi.nlm.nih.gov/pubmed/19138360. Go to original source... Go to PubMed...
    26. Kedia GT, Ückert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 2008; 26(6): 603-609. (Level 4). http://www.ncbi.nlm.nih.gov/pubmed/18607596. Go to original source... Go to PubMed...
    27. Klečka J, Běhounek P, Hora M, et al. Benigní hyperplazie prostaty, diagnostika a současná farmakologická léčba. Prakt. Lékáren. 2010; 6(1): 9-14. http://www.solen.cz/artkey/lek201001-0003_Benigni_hyperplazie_prostaty_diagnostika_a_soucasna_farmakologicka_lecba.php?back=%2Fsearch.php%3Fquery%3Dkle%E8ka%26sfrom%3D0%26spage%3D30.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.